Bloom & Plume

Bloom Science is a clinical-stage biotechnology company focused on developing novel live biotherapeutic products (LBPs) that target the gut-brain axis to treat neurological and metabolic disorders. The company's proprietary IrisRx platform identifies specific gut microbes and metabolites that replicate the therapeutic effects of the ketogenic diet. Its lead candidate, BL-001, is being evaluated for the treatment of Dravet syndrome and obesity, while BL-002 is in development for amyotrophic lateral sclerosis (ALS). Bloom Science aims to provide safer and more effective treatments by leveraging the natural symbiotic relationship between the microbiome and human physiology.